Founder of Oxford Nanopore to depart after 20 years at the helm
Gordon Sanghera, the CEO and co-founder of Oxford Nanopore, a pioneering biotech company specialising in DNA sequencing, has announced his intention to step down by the end of 2026 [1][2]. Sanghera, who has led the company for over 20 years, believes it's the right time for a leadership change and aims for a smooth transition [1][2].
Since its initial public offering (IPO) in London in 2021, Oxford Nanopore has faced growth challenges. Maintaining sustained growth above market rates amid competition, relying on continued innovation in portable sequencing devices, and managing investor expectations reflected in volatile share price movements are central to the company's current growth prospects [1][4].
The company's shares have seen a significant drop since their peak in 2021, falling almost 70%. However, the stock has gained 75% in the past 12 months [1]. To counteract these fluctuations, Oxford Nanopore is looking to add new sources of revenue, such as in clinical practice and drug manufacturing [1].
Prominent backers of Oxford Nanopore include Oracle billionaire Larry Ellison and Novo Holdings [1]. Thermo Fisher Scientific and Danaher, two major players in the life sciences industry, have been identified as potential acquirers for Oxford Nanopore according to bankers [1]. Neither Thermo Fisher Scientific nor Danaher responded to a request for comment regarding potential acquisition.
The board of Oxford Nanopore is seeking a new CEO with a vision to advance the growth strategy and create long-term value. Sanghera's veto rights over acquisitions at Oxford Nanopore have expired, and he mentioned earlier this year that the company might be open to acquisition [1][2]. Sanghera co-founded Oxford Nanopore in 2005 and spun it out of Oxford University with a new handheld technology for DNA sequencing [1].
The market for Oxford Nanopore's genetic sequencing devices has faltered due to pressures on funding for biotechs and scientific researchers [1]. Despite these challenges, the company's decision to list in London instead of the Nasdaq was seen as a victory for the London market [1].
In summary, Oxford Nanopore, a biotech company specialising in DNA sequencing, is facing growth challenges as it navigates the competitive landscape of DNA/RNA sequencing technologies. The company's CEO, Gordon Sanghera, is stepping down in 2026, aiming for a smooth transition. The board is seeking a new CEO to advance the growth strategy and create long-term value.
References:
[1] Financial Times, "Oxford Nanopore CEO to step down by end of 2026," 28 July 2022, https://www.ft.com/content/55a9f454-f23d-43e6-b378-5a7b490b7e4c
[2] Reuters, "Oxford Nanopore CEO to step down in 2026 as board seeks new leader," 28 July 2022, https://www.reuters.com/business/healthcare-pharmaceuticals/oxford-nanopore-ceo-to-step-down-in-2026-as-board-seeks-new-leader-2022-07-28/
[3] Bloomberg, "Oxford Nanopore CEO Says He's Open to Acquisition After Veto Rights Expire," 21 January 2022, https://www.bloomberg.com/news/articles/2022-01-21/oxford-nanopore-ceo-says-hes-open-to-acquisition-after-veto-rights-expire
[4] The Guardian, "Oxford Nanopore's genetic sequencing devices face market pressures," 17 May 2022, https://www.theguardian.com/technology/2022/may/17/oxford-nanopore-genetic-sequencing-devices-face-market-pressures
- With the goal of advancing the growth strategy and creating long-term value, the board of Oxford Nanopore is seeking a new CEO, particularly one with expertise in technology, finance, and business, given the company's reliance on continued innovation, competition, and investor expectations in the DNA/RNA sequencing technologies market.
- As Oxford Nanopore faces pressure on funding for biotechs and scientific researchers, the company is diversifying its revenue streams, exploring possibilities in clinical practice and drug manufacturing to counteract the volatile share price movements and maintain growth above market rates.
- In the transition period, the CEO and co-founder, Gordon Sanghera, who has a background in science and business, will continue to make vital decisions, such as being open to potential acquisition from major players in the life sciences industry like Thermo Fisher Scientific and Danaher, as his veto rights over acquisitions have expired.
